Synlett 2014; 25(12): 1721-1724
DOI: 10.1055/s-0033-1340186
letter
© Georg Thieme Verlag Stuttgart · New York

N,N′-Dibenzosuberyl-1,1′-Binaphthyl-2,2′-diamine: A Highly Effective Supporting Ligand for the Enantioselective Cyclization of Aminoalkenes Catalyzed by Chelating Diamide Complexes of La(III) and Y(III)

Khoi Huynh
Department of Chemistry and Biochemistry, 103 CBB, Montana State University, Bozeman, MT 59717, USA   Fax: +1(406)9945407   Email: livinghouse@chemistry.montana.edu
,
Tom Livinghouse*
Department of Chemistry and Biochemistry, 103 CBB, Montana State University, Bozeman, MT 59717, USA   Fax: +1(406)9945407   Email: livinghouse@chemistry.montana.edu
,
Helena M. Lovick
Department of Chemistry and Biochemistry, 103 CBB, Montana State University, Bozeman, MT 59717, USA   Fax: +1(406)9945407   Email: livinghouse@chemistry.montana.edu
› Author Affiliations
Further Information

Publication History

Received: 13 March 2014

Accepted after revision: 28 April 2014

Publication Date:
12 June 2014 (online)


Abstract

Enantioselective hydroamination/cyclization of representative aminoalkenes catalyzed by chelating diamide complexes of La(III) and Y(III) are described. It is noteworthy that the La(III) complex derived from the sterically demanding (R)-N,N′-dibenzosuberyl-1,1′-binaphthyl-2,2′-diamine proligand provides enantioselectivities that are in many cases significantly higher than those obtained with the corresponding Y(III) analogue. In addition, the presence of LiCl was typically found to suppress both the rates and the enantioselectivities obtained with the Y(III) complex when compared to its La(III) counterpart, in addition to completely suppressing the bicyclization of 7b. The amide complexes employed in the latter study were prepared by ‘amine elimination’ using the new, highly active bases La[N(TMS)(t-Bu)]3 and Y[N(TMS)(t-Bu)]3.

Supporting Information

 
  • References and Notes

    • 1a Crimmin MR, Arrowsmith M, Barrett AG. M, Casely IJ, Hill MS, Procoplou PA. J. Am. Chem. Soc. 2009; 131: 9670 ; and references cited therein
    • 1b Takemiya A, Hartwig JF. J. Am. Chem. Soc. 2006; 128: 6042
    • 1c Bauer EB, Andavan GT. S, Hollis TK, Rubio RJ, Cho J, Kuchenbeiser GR, Helgert TR, Letko CS, Tham FS. Org. Lett. 2008; 10: 1175
    • 1d Julian LD, Hartwig JF. J. Am. Chem. Soc. 2010; 132: 13813
    • 1e Takaya J, Hartwig JF. J. Am. Chem. Soc. 2005; 127: 5756
    • 1f Knodo T, Okada T, Suzuki T, Mitsudo TJ. Organomet. Chem. 2001; 622: 149
    • 1g Fadini L, Togni A. Tetrahedron: Asymmetry 2008; 19: 2555
    • 1h Fadani L, Togni A. Chem. Commun. 2003; 30
    • 1i Pawlas J, Nakao Y, Kawatsura M, Hartwig JF. J. Am. Chem. Soc. 2002; 124: 3669
    • 1j Cochran BM, Michael FE. J. Am. Chem. Soc. 2008; 130: 2786
    • 1k Michael FE, Cochran BM. J. Am. Chem. Soc. 2006; 128: 4246
    • 1l Nettekoven U, Hartwig JF. J. Am. Chem. Soc. 2002; 124: 1166
    • 1m Narsireddy M, Yamamoto Y. J. Org. Chem. 2008; 73: 9698
    • 1n Shaffer AR, Schmidt JA. R. Organometallics 2008; 27: 1259
    • 1o Siriwardana A, Kamada I, Nakamura MI, Yamamoto Y. J. Org. Chem. 2005; 70: 5932
    • 1p Shimada T, Yamamoto Y. J. Am. Chem. Soc. 2002; 124: 12670
    • 1q LaLond RL, Wang ZJ, Mba M, Lackner AD, Toste FD. Angew. Chem. Int. Ed. 2010; 49: 598
    • 1r Widenhofer RA, Han X. Eur. J. Org. Chem. 2006; 4555 ; and references cited therein
    • 1s Leseurre L, Toullec PV, Genet J, Michelet V. Org. Lett. 2007; 9: 4049
    • 2a Hong S, Marks TJ. Acc. Chem. Res. 2004; 37: 673 ; and references cited therein
    • 2b Jiang T, Livinghouse T. Org. Lett. 2010; 12: 4271
    • 2c Kim JY, Livinghouse T. Org. Lett. 2005; 7: 4391
    • 2d Kim YK, Livinghouse T. Angew. Chem. Int. Ed. 2002; 41: 3645
    • 2e Lovick HM, An DK, Livinghouse T. Dalton Trans. 2011; 40: 7697
    • 2f Gribkov DV, Hultzsch KC, Hampel F. J. Am. Chem. Soc. 2006; 128: 3748 ; and references cited therein
    • 2g Kim JY, Livinghouse T, Horino Y. J. Am. Chem. Soc. 2003; 125: 9560
    • 2h Kim JY, Livinghouse T. Org. Lett. 2005; 7: 1737
    • 2i Jiang T, Huynh K, Livinghouse T. Synlett 2013; 24: 193
    • 2j Jiang T, Livinghouse T, Lovick HM. Chem. Commun. 2011; 12861
    • 2k Champurnia Y, Guillot R, Lyubov D, Trifonov A, Hannedouche J, Schulz E. Dalton Trans. 2013; 42: 507
    • 2l Aillaud I, Collin J, Duhayon C, Guillot R, Lyubov D, Schulz E, Trifonov A. Chem. Eur. J. 2008; 14: 2189
    • 2m Yu X, Marks TJ. Organometallics 2007; 26: 365
    • 2n Chapurina Y, Ibrahim H, Guillot R, Kolodziej E, Collin J, Trifonov A, Schulz E, Hannedouche J. J. Org. Chem. 2011; 76: 10163
    • 2o Reznichenko AL, Hultzsch KC. Organometallics 2013; 32: 1394
    • 2p Leitch DC, Payne PR, Dunbar CR, Schafer LL. J. Am. Chem. Soc. 2009; 131: 18246
    • 2q Reznichenko AL, Hultzsch KC. Organometallics 2010; 29: 24
    • 2r Wood MC, Leitch DC, Yeung CS, Kozak JA, Schafer LL. Angew. Chem. Int. Ed. 2007; 46: 354
    • 2s Kim H, Lee PH, Livinghouse T. Chem. Commun. 2005; 41: 5205
    • 2t Thomson RK, Bexrud JA, Schafer LL. Organometallics 2006; 25: 4069
    • 2u Allan LE. N, Clarkson GJ, Fox DJ, Gott AL, Scott P. J. Am. Chem. Soc. 2010; 132: 15308
    • 2v Kubiak R, Prochnow I, Doye S. Angew. Chem. Int. Ed. 2009; 48: 1153
    • 2w Watson DA, Chiu M, Bergman RG. Organometallics 2006; 25: 4731
    • 2x Bexrud JA, Beard JD, Leitch DC, Schafer LL. Org. Lett. 2005; 7: 1959
    • 2y Swartz II D. L, Staples RJ, Odom AL. Dalton Trans. 2011; 40: 7762
  • 3 The complex (TMS-CH2)3La(THF)1.5 (3b) undergoes slow decomposition at 23 °C and must be used immediately upon its generation.
  • 4 Alternatively, the complexes 4a,b could be prepared in THF. In these cases the THF was removed in vacuo and replaced with C6D6 prior to the addition of the aminoalkene.
  • 5 Enantiomeric excesses were determined by conversion of the pyrrolidine products to the corresponding Mosher’s amides followed by 19F NMR spectroscopic evaluation, and comparison to authentic racemates.
  • 6 We have previously observed a related suppression of activity when a Lu(III) complex derived from similar proligand type was used for hydroamination/cyclization (see ref. 2e).
  • 7 Preparative scale (1 mmol) reactions were conducted with the aminoalkenes 7b and 7d. In these cases the pyrrolidines 8b (see ref. 10) and 8d were isolated as the corresponding N-tosylamides in 68% and 71% yields, respectively after purification by column chromatography.
  • 8 Tris(amide)s 5a and 5b were readily prepared from preformed LiN(TMS)(t-Bu) and YCl3 or LaCl3(THF)1.5 in Et2O or THF, respectively, followed by removal of the solvent and sublimation.
  • 9 For a highly enantioselective Y(III) catalyst, see: Manna K, Kruze ML, Sadow AD. ACS Catal. 2011; 1: 1637
  • 10 (S)-4,4-Diallyl-2-methyl-1-tosylpyrrolidine: In an argon-filled glove box, YCl3(THF)3.5 (8.21 mg, 0.02 mmol) and THF (0.5 mL) were added into a J. Young NMR tube equipped with teflon screw cap. (Trimethylsilyl)-methyllithium (5.8 mg, 0.06 mmol) was added and reactant mixture was kept at r.t. for 30 min. N,N′-Bis(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-[1,1′-binaphthalene]-2,2′-diamine (2; 13.84 mg, 0.021 mmol) was added and the solution was maintained at r.t. overnight. Removal of THF in vacuo was then followed by addition of C6D6 (0.5 mL). The 2,2-diallylpent-4-en-1-amine (7b; 0.18 g, 1.1 mmol) was added to the preformed complex and the reactant mixture was subsequently kept at 21 °C for 21 h. Following pyrrolidine formation, the teflon screw cap was removed, the contents were diluted with CH2Cl2 (4 mL) and then transferred into a 5-mL, round-bottomed flask. TsCl (0.36 g, 1.6 mmol) and pyridine (0.2 mL, 1.64 mmol) were added in succession. The reactant mixture was stirred at 21 °C for 12 h. The reactant mixture was diluted with Et2O (20 mL), washed with sat. NaHCO3 (10 mL) and brine (10 mL). The organic phase was subsequently dried with MgSO4. Concentration in vacuo followed by flash chromatography on silica gel (hexane–EtOAc, 20:1) afforded (S)-4,4-diallyl-2-methyl-1-tosylpyrrolidine (0.24 g, 0.75 mmol, 68%). 1H NMR (500 MHz, CDCl3): δ = 7.73 (d, J = 8.2 Hz, 2 H, 2 × ArH), 7.32 (d, J = 7.9 Hz, 2 H, 2 × ArH), 5.68–5.73 (m, 1 H, CH2CH=C), 5.52–5.58 (m, 1 H, CH2CH=C), 4.97–5.09 (m, 3 H, CH2CH=CH 2), 4.80–4.83 (m, 1 H, CH2CH=CH 2), 3.61–3.63 (m, 1 H, CH2CHCH3), 3.17 (dd, J = 41.7, 10.6 Hz, 2 H, CH2N), 2.34–2.52 (m, 3 H, ArMe), 2.12 (d, J = 7.3 Hz, 2 H, CH 2CHCH3), 1.86 (dd, J = 12.8, 7.3 Hz, 1 H, CHCH 3), 1.72 (dd, J = 13.9, 6.8 Hz, 1 H, CHCH 3), 1.57 (dd, J = 13.9, 7.8 Hz, 1 H, CHCH 3), 1.40 (d, J = 6.1 Hz, 4 H, 2 × CH 2CH=C). 13C NMR (126 MHz, CDCl3): δ = 143.6, 135.7, 134.2, 133.9, 129.9, 127.8, 118.7, 58.6, 55.7, 44.9, 43.6, 41.3, 39.9, 30.1, 22.9, 21.9. IR (film): 3072, 2972, 2920, 1638, 1601, 1442, 1342, 1158, 1095, 917, 658, 585 cm–1. HRMS (ESI): m/z [M + H]+ calcd for C18H25NO2S: 320.1679; found: 320.1660.